Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.

ABSTRACT:

Background

Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD).

Objective

To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial.

Animals

Three-hundred-and-thirty-eight dogs with cAD.

Materials and methods

Dogs were randomised to receive oclacitinib (0.4-0.6 mg/kg twice daily for 14 days; then once daily) or ilunocitinib (0.6-0.8 mg/kg once daily), for up to 112 days. Owners assessed pruritus using an enhanced Visual Analog Scale (PVAS). Investigators assessed skin lesions using the Canine Atopic Dermatitis Extent and Severity Index, 4th interaction (CADESI-04).

Results

Reductio

SUBMITTER: Forster S 

PROVIDER: S-EPMC11885073 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature